Tempest gets fast track designation from FDA for amezalpat
Source: SeekingAlpha
2025-02-10 08:26:35 ET
More on Tempest Therapeutics
- Seeking Alpha’s Quant Rating on Tempest Therapeutics
- Historical earnings data for Tempest Therapeutics
- Financial information for Tempest Therapeutics
Read the full article on Seeking Alpha
For further details see:
Tempest gets fast track designation from FDA for amezalpat
Tempest Therapeutics Inc.
NASDAQ: TPST
TPST Trading
-2.5% G/L:
$2.34 Last:
24,792 Volume:
$2.38 Open:
TPST Latest News
March 11, 2026 08:00:00 am
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
February 25, 2026 07:59:00 am
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 11, 2026 06:59:00 am
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
February 04, 2026 04:47:13 pm
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
TPST Stock Data
$11,923,730
4,617,735
0.1%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
Brisbane
